anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To provide an immunoconjugate composed of a monoclonal antibody against a specific tumor cell and a ligand fused to the antibody and exhibiting a specific bioactivity specific to the tumor cell, having excellent antitumor action and useful as an agent for treating tumors such as melanoma and carcinoma. CONSTITUTION: This immunoconjugate is composed of (A) a monoclonal antibody (fragment) against a tumor cell having antigen epitope of an epithelial proliferation factor receptor, e.g. a monoclonal antibody (fragment) originated from mouse, hominized or chimera Mab425 and (B) a ligand fusible to the component A to exhibit biological activity to specifically lyse a tumor cell in situ or induce a tumor-specific immunoresponce, e.g. a cytokine such as TNFα. The conjugate is e.g. Mab425-CH1-TNFα. The immunoconjugate can be produced by fusing DNA sequences coding for the component A and the component B, introducing the construct into an expression vector, transforming a host cell with the vector, culturing the host cell and collecting from the cultured liquid.
Nowadays, the heavy demands placed on health systems exceed the resources in many developed countries. So-called "common mental disorders" and their mostly pharmacological treatment are, in no small part, responsible for this situation. The cost that these disorders generate to the public health service is very high and they are usually associated with other issues like hyperfrequentation and side effects. However, research indicates that psychological treatment should be the first step when caring for these types of problems. We expect that the results show that extensive psychological therapy and combined treatment were the most effective. Nevertheless, brief psychological treatment is expected to be the most efficient in cost-benefit terms.
A complex having the formula (oxytetracycline)3- Mg2B2 wherein B is an ammonium or substituted ammonium ion is prepared by treating an aqueous solution of oxytetracycline base with 2/3 mole of magnesium chloride or magnesium gluconate per mole of oxytetracyline, adjusting the pH to about 8,5 to 9,5 with ammonia or an amine and isolating the complex by freeze-drying or by precipitation with a non-solvent for the complex e.g. alcohol or acetone.  The complex (oxytetracycline)3-Mg2H2 may be prepared by dissolving amphoteric oxytetracycline dihydrate in a solution of MgCl2 in methanol and adding the solution dropwise to an aqueous sodium hydroxide solution whilst maintaining the pH at 6,5 to 7,0.  Both complexes may be used in the preparation of injectable compositions (see Group VI).ALSO:A stable injectable composition is prepared by dissolving in an aqueous solution containing from 25-80% by weight of a C1-6 aliphatic carboxamide (e.g. the amide of acetic or lactic acid) from 10 to 100 mg/ml. of oxytetracycline or an acid addition salt thereof, from 0.67 to 1.0 molar equivalents of a soluble, physiologically acceptable magnesium salt (preferably MgCl2) per mol. of oxytetracycline and sufficient ammonia or a physiologically acceptable, water-soluble C1-6 aliphatic amine having a dissociation constant greater than 10-6 to give the composition a pH of about 8.5 to 9.5.  Antioxidants e.g. sodium bisulphite, -metabisulphite or -formaldehyde sulphoxylate may be added.  For intravenous injection the compositions may be made isotonic e.g. with glucose, saline or Ringer's solution and the pH may be adjusted with inorganic bases sodium hydroxide, carbonate or phosphate in place of the ammonia or amine if the oxytetracycline concentration is low (10-25 mg/ml.). Alternatively, the compositions may be prepared by first making the complex (oxytetracycline)3Mg2B2, where B represents the ammonium or substituted ammonium ion or the parent acid thereof (see Group IV (b)), adjusting the pH and dissolving in the amide solution.  Specified amides are N,N-dimethyl- and diethyl-acetamide, acetamide, N-(b -hydroxyethyl)-lactamide. Specified amines are ethanolamine (preferred), mono-, di- and tri-ethylamine, diethanolamine, argonine and glucosamine.  The amphoteric form of oxytetracycline is preferred.
Problem solving as developed by Nexu and colleguages. First-line managers are trained in the problem solving intervention (1 1/2 day). Thereafter, they apply the problem-solving in 2 - 5 meetings (about 30 - 45 min each) with employees at risk of future sick leave due to common mental disorders.
The soap holder has a plate in contact with the soap which is permeable to water. The plate is made in earthenware and it has grooves, hollows or studs and it can have holes through it. The part which supports the soap can be flat. The plate can be made in sandstone or porcelain. It can be incorporated in a soap holder during its manufacture or it can be added to any soap holder. It can form the soap holder itself.
BACKGROUND: Mitochondrial dysfunction and metabolic reprogramming can lead to the development and progression of hepatocellular carcinoma (HCC). Ferredoxin 1 (FDX1) is a small mitochondrial protein and recent studies have shown that FDX1 plays an important role in tumor cuproptosis, but its role in HCC is still elusive. In this study, we aim to investigate the expression and novel functions of FDX1 in HCC.
METHODS: FDX1 expression was first analyzed in publicly available datasets and verified by immunohistochemistry, qRT-PCR and Western blot. In vitro and in vivo experiments were applied to explore the functions of FDX1. Non-targeted metabolomics and RNA-sequencing were used to determine molecular mechanism. mRFP-GFP-LC3 lentivirus transfection, Mito-Tracker Red and Lyso-Tracker Green staining, transmission electron microscopy, flow cytometry, JC-1 staining, etc. were used to analyze mitophagy or ROS levels. Hydrodynamic tail vein injection (HTVi) and patient-derived organoid (PDO) models were used to analyze effect of FDX1 overexpression.
RESULTS: FDX1 expression is significantly downregulated in HCC tissues. FDX1 downregulation promotes HCC cell proliferation, invasion in vitro and growth, metastasis in vivo. In addition, FDX1 affects metabolism of HCC cells and is associated with autophagy. We then confirmed that FDX1 deficiency increases ROS levels, activates mitophagy and the PI3K/AKT signaling pathway in HCC cells. Interestingly, scavenging ROS attenuates the tumor-promoting role and mitophagy of FDX1 downregulation. The results of HTVi and PDO models both find that FDX1 elevation significantly inhibits HCC progression. Moreover, low FDX1 expression is associated with shorter survival and is an independent risk factor for prognosis in HCC patients.
CONCLUSIONS: Our research had investigated novel functions of FDX1 in HCC. Downregulation of FDX1 contributes to metabolic reprogramming and leads to ROS-mediated activation of mitophagy and the PI3K/AKT signaling pathway. FDX1 is a potential prognostic biomarker and increasing FDX1 expression may be a potential therapeutic approach to inhibit HCC progression.
Participants in the intervention group will be offered a dietitian-delivered intervention over 6 months, similar to the NHS pilot of low calorie diets for type 2 diabetes remission. The intervention starts with 12 weeks of low-energy total diet replacement (approx. 860 kcal/day) in a nutritionally replete package of soups, shakes, and bars. It continues with stepped food reintroduction (maximum 6 weeks) as a low-calorie, nutrient-rich diet personalised to the individual participant circumstances and preferences, and weight maintenance (6 weeks).
Adipogenesis significantly contributes to healthy adipose tissue expansion in obesity. Increasing adipocyte number or function to alleviate adipose tissue overload could serve as a therapeutic strategy for both lipodystrophy and obesity-related metabolic syndrome. Inorganic pyrophosphatase (PPA1) is an enzyme that catalyzes the hydrolysis of pyrophosphate (PPi) and is involved in many biochemical reactions, but its function in adipose tissue has not been studied previously. In this study, we demonstrated that adipose-specific PPA1 knockout (PPA1AKO) mice showed lipodystrophy and spontaneously developed hepatic steatosis and severe insulin resistance under normal chow diet feeding. PPA1 deficiency suppressed the differentiation of primary adipocyte precursors and 3T3-L1 cells. Notably, PPA1 overexpression can restore inhibited adipogenesis in preadipocytes isolated from db/db mice and type 2 diabetes patients. Mechanistic studies have revealed that PPA1 acts as a positive regulator of early adipocyte differentiation by promoting CCAAT/enhancer-binding proteinβ and δ (C/EBPβ and δ) protein stability. Moreover, the function of PPA1 in adipogenesis is independent of its PPi catalytic activity. Collectively, our in vivo and in vitro findings demonstrated that PPA1 is a novel critical upstream regulator of adipogenesis, controlling adipose tissue development and whole-body metabolic homeostasis.
An electrical connector includes an insulative housing and several contacts fixed in the insulative housing. The insulative housing includes a tongue. The tongue includes a first mating surface and a second mating surface. A first group of passages are formed on the first mating surface and a second group of passages are formed on the second mating surface. The contacts include a first group of the contacts fixed in the first passages and a second group of the contacts fixed in the second passages. Two contacts of the first group are used to transmit the USB Power. Two contacts of the second group are used to transmit power which is different from the USB power. The electrical connector can transmit two different kind of power at the same time.
Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity. The sulfatase activity deficiency results in the accumulation of the GAG substrates, KS and C6S, in the lysosomal compartment of cells throughout the body. The accumulation leads to widespread cellular, tissue, and organ dysfunction. Vimizim is intended to provide the exogenous enzyme N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S. Elosulfase alfa uptake by cells into lysosomes is mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of elosulfase alfa to mannose-6-phosphate receptors.

In the absence of an animal disease model that recapitulates the human disease phenotype, elosulfase alfa pharmacological activity was evaluated using human primary chondrocytes from two MPS IVA patients. Treatment of MPS IVA chondrocytes with elosulfase alfa induced clearance of KS lysosomal storage from the chondrocytes.
Interferons bind to specific cell surface receptors and initiate a sequence of intracellular events that lead to the transcription of interferon-stimulated genes. The three major groups of interferons (alpha, beta, gamma) have partially overlapping biological activities that include immunoregulation such as increased resistance to microbial pathogens and inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind to the alpha/ beta receptor. Interferon gamma binds to a different cell surface receptor and is classified as Type 2 interferon. Specific effects of interferon gamma include the enhancement of the oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), activation of natural killer (NK) cells, and the expression of Fc receptors and major histocompatibility antigens.

CGD is an inherited disorder of leukocyte function caused by defects in the enzyme complex responsible for phagocyte superoxide generation. ACTIMMUNE does not increase phagocyte superoxide production even in treatment responders.

In SMO (an inherited disorder characterized by an osteoclast defect, leading to bone overgrowth, and by deficient phagocyte oxidative metabolism), a treatment-related enhancement of superoxide production by phagocytes was observed. ACTIMMUNE was found to enhance osteoclast function in vivo.

In both disorders, the exact mechanism(s) by which ACTIMMUNE has a treatment effect has not been established. Changes in superoxide levels during ACTIMMUNE therapy do not predict efficacy and should not be used to assess patient response to therapy.
Caregivers in this group will be asked to participate in a 13-session program (Corazones) delivered via Zoom. Caregivers will be asked to complete study questionnaires at the beginning of the study (Baseline), after completing the 13 zoom-based sessions (T2) and 3 months after participating in the program (T3). Caregivers will also be asked to participate in an interview with members of the research team to discuss their experiences participating in the program.
Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
The invention belongs to the technical field of gene therapy and diagnosis, in particular relates to the application of a tumor antigen gene XAGE-1 and expression products thereof in tumor therapy and diagnosis. The vital function of XAGE-1 gene in the growth and the transfer of tumors is found for the first time herein, and XAGE-1 gene is an important symbol of tumors. According to the research, XAGE-1 can promote proliferation, transfer and invasion capabilities of cells of adenoid cystocarcinoma of salivary gland and various tumor cells. The gene and the expression products thereof can be used as drug targets to develop various tumor treatment drugs, in particular the drugs for resisting the growth and transfer of tumors. XAGE-1 and the expression products thereof can be used as the symbols of tumors for tumor diagnosis and analysis of illness, and for developing various diagnostic reagent kits and methods, thus significantly improving the diagnosis level of tumors, in particular incipient tumors. The specificity regulatory sequence of XAGE-1 can be applied in tumor therapy and so on according to the transcriptional regulatory mechanism of XAGE-1.
A list of patients registered in primary care centers of the Balearic Islands and potentially meeting the eligibility criteria will be obtained from electronic health records (EHRs). A research assistant will contact the potential participants via phone to invite them to the study and confirm eligibility. All eligible participants will complete informed consent followed by baseline assessment over the phone before randomization. Participants will be randomly allocated using a computer-generated randomization sequence. All participants will continue with their usual diabetes care including all medical visits, tests, and diabetes support programs throughout the study. In addition, the intervention group will receive the text messaging intervention. Control participants will receive usual care only. After three months of follow-up, all participants will complete post-intervention assessments via phone interview. Data on glycemic control (HbA1c) at baseline and post-intervention will be extracted from EHRs, as according to the protocol used for primary care providers in the Balearic Islands, patients with poor glycemic control (HbA1c \>8% ) must request an HbA1c determination every six months. Results of the most recent determination will be extracted from electronic medical records. For those patients with no recorded HbA1c within the previous three months, the research assistant will contact the primary care center and the patient to arrange blood test analyses.
Three scales (knowledge, attitude, self-efficacy) in the "Sexual Healthcare Questionnaire" will be applied to 2nd and 3rd year nursing students. The scales will be re-administered to at least 30 students within 4 weeks.
The invention discloses a VEGF (Vascular Endothelial Growth Factor) resistant antibody belonging to the fields of biotechnology and immunology and application of the VEGF resistant antibody. Amino acid sequences of three complementary determining regions (CDR) of heavy chain variable regions of the antibody are respectively shown as SED ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3; the amino acid sequences of the three complementary determining regions of light chain variable regions of the antibody are respectively shown as SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. According to the VEGF resistant humanized antibody, specific targeting combines with VEGF antigens, and an antibody affinity is 3.11*10<-10>, the binding capacity of the antibody and the antigens is high; the VEGF resistant humanized antibody has a good biological activity and can inhibit cell proliferation of vascular endothelial cells, obviously inhibit tumor growth, and effectively inhibit the growth of corneal neovascularization, and can be used for preparing targeted medicines of specific targeting VEGF antigens or angiogenesis inhibiting medicines.
Supervisors Lise Hounsgaard, Associate Professor, PhD, Research Unit of Nursing, Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark. Lone Kjeld Petersen, Consultant, DMSc. and Jan Blaakær, Consultant, DMSc.Department of Gynaecology and Obstetrics Y, Aarhus University Hospital, Skejby.

Funding Faculty of Health Sciences, University of Southern Denmark. Department of Gynaecology and Obstetrics Y, Aarhus University Hospital, Skejby. The Research Foundation of Health Science in Central Denmark Region. The Research Foundation of Aarhus University Hospital, Skejby. The Hede Nielsen Foundation. The Danish Cancer Society, Psychosocial Research Committee. Tha Danish Nurses organisation
The dysregulation of long non-coding RNAs (lncRNAs) are involved in regulating tumor progression in multiple manner. However, little is known about whether lncRNA is involved in the translation regulation of proteins. Here, we identified that the suppressor of inflammatory macrophage apoptosis lncRNA (SIMALR) was highly expressed in nasopharyngeal carcinoma (NPC) tissues by analyzing the lncRNA microarray. Clinically, the high expression of SIMALR served as an independent predictor for inferior prognosis in NPC patients. SIMALR functioned as an oncogenic lncRNA that promoted the proliferation and metastasis of NPC cells in vitro and in vivo. Mechanistically, SIMALR served as a critical accelerator of protein synthesis by binding to eEF1A2 (eukaryotic translation elongation factor 1 alpha 2), one of the most crucial regulators in the translation machinery of the eukaryotic cells, and enhancing its endogenous GTPase activity. Furthermore, SIMALR mediated the activation of eEF1A2 phosphorylation to accelerate the translation of ITGB4/ITGA6, ultimately promoting the malignant phenotype of NPC cells. In addition, N-acetyltransferase 10 (NAT10) enhanced the stability of SIMALR and caused its overexpression in NPC through the N4-acetylcytidine (ac4C) modification. In sum, our results illustrate SIMALR functions as an accelerator for protein translation and highlight the oncogenic role of NAT10-SIMALR-eEF1A2-ITGB4/6 axis in NPC.
Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
PURPOSE:To provide the titled donor capable of releasing the drug in a living body under controlled condition, by dissolving chitin in a solvent, contacting the obtained dope with a coagulating liquid to obtain swollen chitin, impregnating the swollen chitin with a drug-containing solution, and drying the product. CONSTITUTION:Chitin (poly-N-acetyl-D-glucosamine) is dissolved in a solvent (e.g. trichloroacetic acid), and the obtained dope is charged in a pressure tank and extruded with a gear pump, etc. through a sepcific die into a coagulating liquid (e.g. water, alcohol, ketone, etc.) to obtain a swollen product having the form of rod, ring, sheet, etc. The product is impregnated with a solution containing a drug (e.g. proteinous drug, anti-infective, carcinostatic agent, remedy for ophthalmic diseases, etc.), and dried to obtain the objective donor. When the donor is brought ino contact with a body fluid, it releases the drug slowly over a lont time into the body fluid, and finally the donor itself also disappears. The releasing period can be adjusted.
PURPOSE: A medicine patch and a manufacturing method thereof are provided to increase yield and prevent loss of medicine by simplifying a cutting process to be one process. CONSTITUTION: A medicine patch comprise a medicine section(1) and a wrapping unit(2). The medicine section comprises a medicine layer(11), a release film layer(12), and a protecting film layer(13). The release film layer is adhered to the lower part of the medicine layer, prevents contamination of the medicine layer, and is removed when attached to an affected part. The wrapping unit is formed with a sealing part(25) which seals four edges, and is sealed. A top wrapping layer(21) is formed with embossing(26) in a fixed interval to have a good release ability for the medicine section. The wrapping unit is formed with 1-2 notch parts(27) which facilitate tearing of the wrapping unit to easily take out the medicine section. [Reference numerals] (AA) Cross section of a medicine part; (BB) Cross section of a sealing part
Twenty female patients who met the American College of Rheumatology diagnostic criteria for the classification of FM were enrolled in the study. Patients were randomly allocated to receive either hydrotherapy or NST. Patient evaluations were performed at baseline, six weeks, three months, and six months. Primary outcome measures included the SF-36 quality of life questionnaire, the Fibromyalgia Impact Questionnaire and the Total Myalgic Score. Duration of morning stiffness and duration of weekly aerobic exercise as reported by the participants were secondary outcome measures. Statistics analysis was performed by standard parametric and non parametric methods.
The proposed study is designed to evaluate the hypothesis that functional connectivity may represent an early marker for neurocognitive improvements related to Kuvan treatment. As a first step in the study, 20 patients with PKU who are ≥ 6 years of age will receive baseline functional connectivity magnetic resonance imaging (fcMRI) evaluations before being treated with Kuvan™. Response to Kuvan™ will be monitored for 4 weeks. At the end of 4 weeks, response to Kuvan™ will be reviewed and all 20 patients will receive follow-up fcMRI evaluations. Fifteen patients with a reduction of ≥ 20% in blood phenylalanine will continue in the study and receive a third fcMRI evaluation at the end of 6 months of treatment with Kuvan™. For comparison purposes and to control for possible practice effects in repeated testing, a matched control group of 20 healthy individuals without PKU will used. All 20 of the control subjects will receive baseline and 4-week fcMRI evaluations; fifteen will receive a 6-month evaluation.
Clemastine fumarate is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines competitively antagonize various physiological effects of histamine including increased capillary permeability and dilatation, the formation of edema, the "flare" and "itch" response, and gastrointestinal and respiratory smooth muscle constriction. Within the vascular tree, H1-receptor antagonists inhibit both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, H1- receptor antagonists can produce CNS stimulation or depression. Most antihistamines exhibit central and/or peripheral anticholinergic activity. Antihistamines act by competitively blocking H1-receptor sites. Antihistamines do not pharmacologically antagonize or chemically inactivate histamine, nor do they prevent the release of histamine.